Literature DB >> 25656504

IL-33 isoforms: their future as vaccine adjuvants?

Daniel O Villarreal1, David B Weiner.   

Abstract

The identification and characterization of cytokine isoforms is likely to provide critical important new insight into immunobiology. Cytokine isoforms can provide additional diversity to their complex biological effects that participate in control and protection against different foreign pathogens. Recently, IL-33 has been identified as a proinflammatory cytokine having several different biologically active isoform products. Originally associated with Th2 immunity, new evidence now supports the role of two IL-33 isoforms to facilitate the generation of protective Th1 and CD8 T cell immunity against specific pathogens. Therefore, a better understanding of the IL-33 isoforms will inform us on how to utilize them to facilitate their development as tools as vaccine adjuvants for immune therapy.

Entities:  

Keywords:  CD8 T cell; DNA vaccine; IL 33; adjuvant; cancer vaccine; cytokine; immunotherapies; isoform

Mesh:

Substances:

Year:  2015        PMID: 25656504      PMCID: PMC4573560          DOI: 10.1586/14760584.2015.1011135

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  23 in total

1.  Novel splice variants of IL-33: differential expression in normal and transformed cells.

Authors:  Hidetoshi Tsuda; Mayumi Komine; Masaru Karakawa; Takafumi Etoh; Shin-Ichi Tominaga; Mamitaro Ohtsuki
Journal:  J Invest Dermatol       Date:  2012-07-12       Impact factor: 8.551

2.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.

Authors:  Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 3.  IL-33/ST2 axis in inflammation and immunopathology.

Authors:  Marija Milovanovic; Vladislav Volarevic; Gordana Radosavljevic; Ivan Jovanovic; Nada Pejnovic; Nebojsa Arsenijevic; Miodrag L Lukic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

4.  Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion.

Authors:  Irina G Luzina; Edward M Pickering; Pavel Kopach; Phillip H Kang; Virginia Lockatell; Nevins W Todd; John C Papadimitriou; Andrew N J McKenzie; Sergei P Atamas
Journal:  J Immunol       Date:  2012-05-25       Impact factor: 5.422

Review 5.  Immunologic messenger molecules: cytokines, interferons, and chemokines.

Authors:  Scott P Commins; Larry Borish; John W Steinke
Journal:  J Allergy Clin Immunol       Date:  2009-11-24       Impact factor: 10.793

Review 6.  Special aspects of interleukin-33 and the IL-33 receptor complex.

Authors:  Michael U Martin
Journal:  Semin Immunol       Date:  2013-11-11       Impact factor: 11.130

7.  Expression analysis and functional activity of interleukin-7 splice variants.

Authors:  N K Vudattu; I Magalhaes; H Hoehn; D Pan; M J Maeurer
Journal:  Genes Immun       Date:  2008-12-18       Impact factor: 2.676

8.  Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system.

Authors:  Yuichi Kondo; Tomohiro Yoshimoto; Koubun Yasuda; Shizue Futatsugi-Yumikura; Mai Morimoto; Nobuki Hayashi; Tomoaki Hoshino; Jiro Fujimoto; Kenji Nakanishi
Journal:  Int Immunol       Date:  2008-04-29       Impact factor: 4.823

9.  Examining IL-33 expression in the cervix of HPV-infected patients: a preliminary study comparing IL-33 levels in different stages of disease and analyzing its potential association with IFN-γ.

Authors:  Lei Wang; Hongying Li; Feng Liang; Yi Hong; Shaowei Jiang; Ling Xiao
Journal:  Med Oncol       Date:  2014-08-09       Impact factor: 3.064

10.  Interleukin-33: a mediator of inflammation targeting hematopoietic stem and progenitor cells and their progenies.

Authors:  Hongnga Le; Wonyoung Kim; Juyang Kim; Hong R Cho; Byungsuk Kwon
Journal:  Front Immunol       Date:  2013-05-06       Impact factor: 7.561

View more
  9 in total

1.  Ambient ozone and influenza transmissibility in Hong Kong.

Authors:  Sheikh Taslim Ali; Peng Wu; Simon Cauchemez; Daihai He; Vicky J Fang; Benjamin J Cowling; Linwei Tian
Journal:  Eur Respir J       Date:  2018-05-10       Impact factor: 16.671

2.  M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection.

Authors:  A R Piñeros; L W Campos; D M Fonseca; T B Bertolini; A F Gembre; R Q Prado; J C Alves-Filho; S G Ramos; M Russo; V L D Bonato
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 3.  The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response.

Authors:  Vikram Mehraj; Rosalie Ponte; Jean-Pierre Routy
Journal:  EBioMedicine       Date:  2016-07-01       Impact factor: 8.143

Review 4.  The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine.

Authors:  Jean-Jacques Fournié; Mary Poupot
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

5.  Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model.

Authors:  Sophia M Reeder; Emma L Reuschel; Mamadou A Bah; Kun Yun; Nicholas J Tursi; Kevin Y Kim; Jacqueline Chu; Faraz I Zaidi; Ilknur Yilmaz; Robert J Hart; Benjamin Perrin; Ziyang Xu; Laurent Humeau; David B Weiner; Ahmed S I Aly
Journal:  Vaccines (Basel)       Date:  2020-01-10

6.  IL-33 Alarmin and Its Active Proinflammatory Fragments Are Released in Small Intestine in Celiac Disease.

Authors:  Federico Perez; Carolina N Ruera; Emanuel Miculan; Paula Carasi; Karen Dubois-Camacho; Laura Garbi; Luciana Guzman; Marcela A Hermoso; Fernando G Chirdo
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 7.  Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.

Authors:  Sara Andreone; Adriana Rosa Gambardella; Jacopo Mancini; Stefania Loffredo; Simone Marcella; Valentina La Sorsa; Gilda Varricchi; Giovanna Schiavoni; Fabrizio Mattei
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

Review 8.  Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation.

Authors:  Ari B Molofsky; Adam K Savage; Richard M Locksley
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

Review 9.  The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity.

Authors:  Claudia Afferni; Carla Buccione; Sara Andreone; Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone; Fabrizio Mattei; Giovanna Schiavoni
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.